menu
    • menu
    [{"orgOrder":0,"company":"Nanexa","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nanexa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection, Prolonged Release","sponsorNew":"Nanexa \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Nanexa \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Nanexa","sponsor":"Uppsala University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NEX-18A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanexa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nanexa \/ Uppsala University","highestDevelopmentStatusID":"6","companyTruncated":"Nanexa \/ Uppsala University"},{"orgOrder":0,"company":"Nanexa","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NEX-20A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nanexa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nanexa \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"6","companyTruncated":"Nanexa \/ CTC Clinical Trial Consultants"}]

    Find Clinical Drug Pipeline Developments & Deals by Nanexa

    Menu

    Nanexa

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Profil Institut für Stoffwechselforschung GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 03, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Profil Institut für Stoffwechselforschung GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEX-20A

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CTC Clinical Trial Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjec...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : NEX-20A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CTC Clinical Trial Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed

                            Nanexa

                            Sweden arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEX-18A

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Uppsala University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Tolerability and Safety of NEX-18a

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 17, 2021

                            Lead Product(s) : NEX-18A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Uppsala University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth